Companies
Symbiotec Pharmalab
Vertically integrated steroid API — Steroid-API specialist, IPO 2026.
- Country
- India
Commercial
Steroid API specialist (IN)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | ₹869.1 crore in FY26 | mailcontent.icicidirect.com · mywealthpost.com · patersoncapital.com |
| Funding | IPO (fresh issue of ₹150 crore and offer for sale of ₹1,607 crore) in August 2026 | mailcontent.icicidirect.com · mywealthpost.com · cnbctv18.com · thehindubusinessline.com |
| Capacity | 584.67 MT (chemical synthesis) and 700 KL (fermentation) | mailcontent.icicidirect.com · mywealthpost.com · symbiotec.com |
| Production site | Rau, Pithampur, Ujjain, and Mhow in Madhya Pradesh, India | mailcontent.icicidirect.com · mywealthpost.com · symbiotec.com |
| Certification | US FDA, EU-GMP, and WHO-GMP certifications | mailcontent.icicidirect.com · mywealthpost.com · pharma.economictimes.indiatimes.com · symbiotec.com |
| Regulatory approval | US FDA, EU-GMP, WHO-GMP, MFDS Korea, and others | mailcontent.icicidirect.com · mywealthpost.com · pharma.economictimes.indiatimes.com · symbiotec.com |
| Headcount | Over 2,500 employees as of March 31, 2026 | mywealthpost.com |
Independent sources: cnbctv18.com · mailcontent.icicidirect.com · mywealthpost.com · patersoncapital.com · pharma.economictimes.indiatimes.com · thehindubusinessline.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biosynthetic steroids (fermentation & biocatalytic API) | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.